Hongming Chen

Hongming Chen is an American chemical engineer.

Not to be confused with Chen Hung-ming.

Chen earned a Bachelor's of Science degree in chemical engineering from the University of Texas at Austin in 1992, and completed a Master's and Doctor of Science in the same subject at the Massachusetts Institute of Technology. She then conducted research at Merck & Co. and AstraZeneca. She later helped establish TransForm Pharmaceuticals, which was later acquired by Johnson & Johnson, and subsequently worked for Kala Pharmaceuticals from its founding in 2010, then cofounded Metis Therapeutics.[1]

In 2015, Chen was elected a fellow of the American Institute for Medical and Biological Engineering.[2][3] She was elected to membership of the United States National Academy of Engineering in 2018.[4]

References
  1. "Five Alumni Honored with Cockrell School Distinguished Graduate Awards for 2021". University of Texas at Austin. 13 September 2022. Retrieved 16 October 2023.
  2. "Hongming Chen, Ph.D. To be Inducted into Medical and Biological Engineering Elite". American Institute for Medical and Biological Engineering. 12 March 2015. Retrieved 16 October 2023.
  3. "HONGMING CHEN, PH.D." American Institute for Medical and Biological Engineering. Retrieved 16 October 2023.
  4. "Dr. Hongming Chen". United States National Academy of Engineering. Retrieved 16 October 2023.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.